[HTML][HTML] Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
EN Oliva, T Ionova, E Laane, M Csenar… - Frontiers in …, 2024 - frontiersin.org
Background Lymphoma treatment can lead to long-term consequences such as fatigue,
infertility and organ damage. In clinical trials, survival outcomes, clinical response and …
infertility and organ damage. In clinical trials, survival outcomes, clinical response and …
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
JC Del Paggio, R Naipaul, S Gavura, RE Mercer… - The Lancet …, 2024 - thelancet.com
Background The financial impact of cancer medicines on health systems is not well known.
We describe temporal trends in expenditure on cancer medicines within the single-payer …
We describe temporal trends in expenditure on cancer medicines within the single-payer …
[HTML][HTML] Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy
S Molica - Expert Review of Hematology, 2023 - Taylor & Francis
The therapeutic landscape for chronic lymphocytic leukemia (CLL) has dramatically
changed during the past ten years with the shift from conventional chemo-immunotherapy …
changed during the past ten years with the shift from conventional chemo-immunotherapy …
[HTML][HTML] List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study
Background High prices of anticancer drugs have raised concerns due to their financial
impact on patients and healthcare systems. This study aimed to assess the initial and latest …
impact on patients and healthcare systems. This study aimed to assess the initial and latest …
Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis …
L Ding, X Yuan, Y Wang, Z Shen, P Wu - BMJ open, 2024 - bmjopen.bmj.com
Objective The aim of this study was to assess the clinical benefit value of approved antibody
drug conjugates (ADCs) for solid tumours using the European Society for Medical Oncology …
drug conjugates (ADCs) for solid tumours using the European Society for Medical Oncology …
[PDF][PDF] Rethinking the reimbursement of innovative medicines in oncology: Looking beyond overall survival
The oncological treatment landscape is evolving at a very rapid pace with a continuous
stream of novel treatment options. To fully leverage these therapeutic advances in clinical …
stream of novel treatment options. To fully leverage these therapeutic advances in clinical …
[HTML][HTML] The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and …
E Julian, O Solà-Morales, MJ Garcia… - Journal of Market …, 2024 - mdpi.com
Background: This work aimed to determine the role and action points for the involvement of
medical societies in the European Health Technology Assessment (EU HTA) Methods: An …
medical societies in the European Health Technology Assessment (EU HTA) Methods: An …
[HTML][HTML] An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders …
T Desmet, E Julian, W Van Dyck, I Huys… - Journal of Market …, 2024 - mdpi.com
Objectives: Stakeholder involvement has long been considered a success factor for a joint
European health technology assessment (HTA) process, and its relevance is now anchored …
European health technology assessment (HTA) process, and its relevance is now anchored …
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
Objective To examine characteristics of clinician input to the pan-Canadian Oncology Drug
Review (pCODR) for cancer drug funding recommendations from 2016 to 2020. Design …
Review (pCODR) for cancer drug funding recommendations from 2016 to 2020. Design …